Navigation Links
Biodel Inc. Announces Pricing of Public Offering
Date:2/7/2008

DANBURY, Conn., Feb. 7 /PRNewswire-FirstCall/ -- Biodel Inc. (Nasdaq: BIOD) today announced the pricing of the underwritten public offering of 3,810,000 shares of its common stock at a price to the public of $15.50 per share. Of the shares being sold in the offering, 3,260,000 shares are being issued and sold by Biodel and 550,000 shares are being sold by certain stockholders of the Company. Biodel expects to receive net proceeds from the offering of approximately $46.4 million, after deducting underwriting discounts and commissions, and estimated offering expenses. Biodel will not receive any proceeds from the sale of shares by the selling stockholders.

In addition, the selling stockholders have granted the underwriters a 30 day option to purchase up to an additional 571,500 shares of common stock to cover over-allotments, if any.

Morgan Stanley & Co. Incorporated is acting as the sole book-runner manager and J.P. Morgan Securities Inc. is acting as co-lead manager for this offering. Leerink Swann LLC and Natixis Bleichroeder Inc. are acting as co-managers.

A registration statement relating to these securities has been filed with and declared effective by the Securities and Exchange Commission. An offer will be made only by means of a prospectus. A final prospectus relating to the offering may be obtained from the Morgan Stanley & Co. Incorporated prospectus department, 180 Varick Street, New York, NY 10014, Attention: Prospectus Department, by telephone at 866-718-1649 or by emailing prospectus@morganstanley.com.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, any of the securities, nor shall there be any sale of these securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for endocrine disorders such as diabetes and osteoporosis.


'/>"/>
SOURCE Biodel Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Ralf Rosskamp, M.D. Joins Biodels Scientific Advisory Board
2. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
3. Biodel to Amend June 30, 2007 10-Q to Correct Non-Cash Share-Based Compensation Expense
4. Biodel Inc. to Present at BIO InvestorForum 2007 Conference on October 11, 2007
5. Biodel Inc. to Present at Natixis Bleichroeder Hidden Gems Conference on October 8, 2007
6. Brian J.G. Pereira, M.D. Joins Biodels Board of Directors
7. Biodel to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on December 11, 2007
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... , ... Supplyframe, the Industry Network for electronics hardware design ... Located in Pasadena, Calif., the Design Lab’s mission is to bring together inventors ... and brought to market. , The Design Lab is Supplyframe’s physical representation of ...
(Date:6/23/2016)...  Blueprint Bio, a company dedicated to identifying, protecting ... has closed its Series A funding round, according to ... "We have received a commitment from Forentis Fund that ... meet our current goals," stated Matthew Nunez . ... complete validation on the current projects in our pipeline, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance ... consulting, provides a free webinar on Performing Quality Investigations: Getting to ... 12pm CT at no charge. , Incomplete investigations are still a major concern ...
(Date:6/22/2016)... , June 22, 2016 Cell Applications, ... allow them to produce up to one billion ... lot within one week. These high-quality, consistent stem ... preparing cells and spend more time doing meaningful, ... a proprietary, high-volume manufacturing process that produces affordable, ...
Breaking Biology Technology:
(Date:4/15/2016)... -- A new partnership announced today will help life ... a fraction of the time it takes today, ... insurance policies to consumers without requiring inconvenient and ... rapid testing (A1C, Cotinine and HIV) and higi,s ... pulse, BMI, and activity data) available at local ...
(Date:4/13/2016)... April 13, 2016  IMPOWER physicians supporting Medicaid patients ... a new clinical standard in telehealth thanks to a ... the higi platform, IMPOWER patients can routinely track key ... body mass index, and, when they opt in, share ... visit to a local retail location at no cost. ...
(Date:3/29/2016)... LegacyXChange, Inc. (OTC: LEGX ... Protect are pleased to announce our successful effort to ... of writing instruments, ensuring athletes signatures against counterfeiting and ... athletes on LegacyXChange will be assured of ongoing proof ... Bill Bollander , CEO states, "By inserting ...
Breaking Biology News(10 mins):